Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) Shares Outstanding (Weighted Average): 2019-2024

Historic Shares Outstanding (Weighted Average) for Silence Therapeutics (SLN) over the last 3 years, with Dec 2024 value amounting to $138.8 million.

  • Silence Therapeutics' Shares Outstanding (Weighted Average) fell 22.76% to $141.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $141.7 million, marking a year-over-year decrease of 22.76%. This contributed to the annual value of $138.8 million for FY2024, which is 0.46% up from last year.
  • Latest data reveals that Silence Therapeutics reported Shares Outstanding (Weighted Average) of $138.8 million as of FY2024, which was up 0.46% from $138.1 million recorded in FY2023.
  • In the past 5 years, Silence Therapeutics' Shares Outstanding (Weighted Average) registered a high of $138.8 million during FY2024, and its lowest value of $119.5 million during FY2022.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $138.1 million (2023), whereas its average is $132.1 million.
  • As far as peak fluctuations go, Silence Therapeutics' Shares Outstanding (Weighted Average) rose by 15.54% in 2023, and later decreased by 0.46% in 2024.
  • Over the past 3 years, Silence Therapeutics' Shares Outstanding (Weighted Average) (MRY) stood at $119.5 million in 2022, then increased by 15.54% to $138.1 million in 2023, then rose by 0.46% to $138.8 million in 2024.
  • Its Shares Outstanding (Weighted Average) stands at $138.8 million for FY2024, versus $138.1 million for FY2023 and $119.5 million for FY2022.